Gsk Share Discussion Threads

[montyhedge] 07/2/2018 12:15

These figures are superb, better than I thought, must admit.

[badtime] 07/2/2018 12:09

I should say I took the quick turn

[stewart64] 07/2/2018 12:09

A rare bit of good news this year.

[badtime] 07/2/2018 12:08

Juju..well done ..I did likewise

[woodhawk] 07/2/2018 12:07

"GSK delivers improvements in sales, margins and cash flow in 2017
Total EPS 31.4p, +67% AER, +36% CER; Adjusted EPS 111.8p, +11% AER,
+4% CER "

And divi safe. Excellent.

[juju44] 07/2/2018 12:06

One of my better calls

[montyhedge] 07/2/2018 12:03

Brilliant, 23p dividend, free cash well up These should be 1425p boys.

[juju44] 07/2/2018 11:50

I have just bought some for the gamble . Left a gap at 1263 - 1275

[abdullla] 07/2/2018 11:43

GSK is direction less until the Pfizer genie is out of the bottle,until then bear with it and live with it,no matter what share price is going down!

[romeike] 07/2/2018 11:32

I've already given up on hope for a sudden rally, just a reversal of the current negative trend trend would be welcome enough at this stage

[montyhedge] 07/2/2018 10:48

If this had been a normal market GSK would have been 1350p on todays rns.But not in normal markets.Fingers crossed at 12pm.

[tradermichael] 07/2/2018 10:36

LONDON (Alliance News) - GlaxoSmithKline PLC said Wednesday it has received breakthrough therapy designation from the US Food & Drug Administration for its meningitis B vaccine Bexsero for prevention of invasive meningococcal disease caused by serogroup B in children aged between two to 10 years.

The FDA's breakthrough therapy designation is designed to expedite the development and review of drugs and vaccines that are intended to treat or prevent serious conditions. Meningitis is a rare medical condition that causes inflammation of the membranes that surround and protect the brain and spinal cord.

Bexsero first received breakthrough therapy designation in 2014 for prevention of invasive meningococcal disease in individuals aged between 10 to 25 years. It was subsequently granted accelerated approval in January 2015.

"This designation emphasises the importance of tackling big scientific challenges like meningitis B and breaking new ground in disease prevention through approaches like reverse vaccinology. GSK is committed to the pursuit of innovative vaccines that help protect against serious diseases with significant unmet need," said GSK Vaccines Chief Scientist Rino Rappuoli.

[nigelpm] 07/2/2018 10:20

If they keep paying decent dividends and generating cash I'm kind of blind to what the market thinks.

[romeike] 07/2/2018 10:18

I am sure the statement will be fine, it is the investor call I am concerned about. Hopefully they have learnt from last time and ditched the "transparency" bullsh1t and treat the analysts with due caution. These aren't your pals Emma, they're after blood.

[abdullla] 07/2/2018 10:06

Catching the falling knife,is not a good idea!

[stewart64] 07/2/2018 09:37

Just hope the statement keeps to the positives. Honest guidance never pays..just dwell on one negative and the shorters and the press will pounce on it like vultures.

Eg Saga mentioned tight margins on insurance..shares halved. Randgold dwelt on the Congolese issue, shares crashed in spite of good results and a rising gold price. ( Congo issue was known but CEO decided to highlight it)

[abdullla] 07/2/2018 09:29

British investors are "chicken "when you compare them with the yanks as you see in the DOW,they don't buy stocks they just short the stocks !

[nigelpm] 07/2/2018 09:14

I agree with Monty albeit I also suspect there's a deliberate lack of buying pre-results - always annoys me they release at midday - should be 7am like most other listed companies.

[bili1946] 07/2/2018 09:07

I hope you are right Monty.
"Beware of Greeks bearing gifts"
Good luck.

[stewart64] 07/2/2018 09:06

Needs to be a good one. The Market is seeing every release as glass half empty. Reckon 80% of releases just lately have been met with price falls.

[romeike] 07/2/2018 09:05

Nice pre results RNS

[montyhedge] 07/2/2018 08:35

Figures released at midday.

[montyhedge] 06/2/2018 22:20

I see this fall as a gift from the stockmarket gods. Topped up.

[polaris] 06/2/2018 21:15

GSK was $35.1 at the close of the LSE, it closed at $36 in the US. Might be a reasonable day for results as it should be a rebound day for the markets in general.

[pugugly] 06/2/2018 21:12

Dow closed up 2.3% GSK and Reckitt in final 2 to bid for consumer goods division


So a two way pull tomorrow - Opening movements will be interesting - Looks as though down after hours in New York but who can tell,